Suppr超能文献

苄基硫氧嘧啶治疗期间抗中性粒细胞胞浆抗体的患病率。

Prevalence of antineutrophil cytoplasmic antibodies during treatment with benzylthiouracil.

作者信息

Sghiri R, Ouertani M, Ben Hsine H, Slim I, Chaieb L, Ghedira I

机构信息

Laboratory of Immunology, Farhat Hached Hospital, Ibn El Jazzar, 4000 Sousse, Tunisia.

出版信息

Pathol Biol (Paris). 2009 Jul;57(5):410-4. doi: 10.1016/j.patbio.2008.11.006. Epub 2009 Feb 6.

Abstract

BACKGROUND

Drug induced antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis is a rare complication associated especially with propylthiouracil (PTU). Prevalence of ANCA in patients receiving PTU is well established. Few cases of vasculitis were also reported with benzylthiouracil (BTU). The objective of this study is to clarify the prevalence of ANCA in patients receiving BTU.

METHODS

ANCA were investigated by indirect immunofluoresence and enzyme linked immunosorbant assay in 159 patients with Graves' disease (86 untreated and 73 treated with BTU).

RESULTS

ANCA were positive in three (3.5%) untreated patients and 27 (37%) treated ones. Titres of ANCA varied between 1:20 and 1:200. There was a significant association between BTU treatment and ANCA (p<0.001). ANCA were directed against myeloperoxidase (MPO) in 28 (93.3%) patients. Median treatment duration was 24 months (ranges 0.5 to 144 months). There was no significant association between treatment duration and ANCA. Vasculitis was found in two (2.7%) treated patients. One patient has developed isolated cutaneous vasculitis and the other one a pulmonary vasculitis with diffuse alveolar haemorrhage.

CONCLUSION

BTU therapy is characterised by a high prevalence of ANCA mainly but not exclusively directed against MPO. However, vasculitis remains a rare complication.

摘要

背景

药物诱导的抗中性粒细胞胞浆抗体(ANCA)相关血管炎是一种罕见的并发症,尤其与丙硫氧嘧啶(PTU)有关。接受PTU治疗的患者中ANCA的患病率已得到充分证实。也有少数苄硫氧嘧啶(BTU)导致血管炎的病例报道。本研究的目的是明确接受BTU治疗的患者中ANCA的患病率。

方法

采用间接免疫荧光法和酶联免疫吸附测定法对159例格雷夫斯病患者(86例未治疗,73例接受BTU治疗)进行ANCA检测。

结果

3例(3.5%)未治疗患者和27例(37%)接受治疗患者的ANCA呈阳性。ANCA滴度在1:20至1:200之间。BTU治疗与ANCA之间存在显著关联(p<0.001)。28例(93.3%)患者的ANCA针对髓过氧化物酶(MPO)。中位治疗持续时间为24个月(范围0.5至144个月)。治疗持续时间与ANCA之间无显著关联。在2例(2.7%)接受治疗的患者中发现血管炎。1例患者发生孤立性皮肤血管炎,另1例发生伴有弥漫性肺泡出血的肺血管炎。

结论

BTU治疗的特点是ANCA患病率高主要但不仅针对MPO。然而,血管炎仍然是一种罕见的并发症。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验